John Adams is an Infectious Disease physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
501 19th Street
Trustees Tower, Suite 600
Knoxville, TN 37916
Telephone
865-331-9160Provider last certified this registry record 19 Jul 2021.
Clinical trials
- Lateralization After IntraMedullary Nailing of InterTrochanteric Hip Fractures, Clinical and Radiographic Outcomes
Sponsor: Prisma Health-Upstate
- Predicting Fluid Responsiveness Using Transiently Increased Intrathoracic Pressure in Mechanically Ventilated Patients
Sponsor: University of California, Davis
- Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function
Sponsor: University of California, Los Angeles
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Laborie Medical Technologies Corp.Program year20251 payment
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20232 payments
- Insmed, Inc.Program year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
87.9%Cephalosporin Antibacterial14.6%Cefuroxime51%Cefazolin Sodium36%Cefdinir14%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor11.7%Juluca39%Cabenuva17%Tivicay17%Isentress15%Isentress Hd13%Part D<11 patients+ 15 more classes in this area
Cardiovascular
3.8%Peroxisome Proliferator-activated Receptor alpha Agonist2.3%Gemfibrozil100%Part D<11 patientsStatin1.5%Atorvastatin Calcium100%Part D<11 patientsHormonal (systemic)
3.1%Growth Hormone Releasing Factor Analog3.1%Egrifta Sv100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”